Back to Search Start Over

A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma:EORTC 1205

Authors :
Raskin, Jo
Surmont, Veerle
Maat, Alexander P.W.M.
Yahia, Maha
Burgers, Sjaak A.
Pretzenbacher, Yassin
De Ryck, Frederic
Cornelissen, Robin
Klomp, Houke M.
Oliveira, Ana
Aerts, Joachim
Baas, Paul
Marreaud, Sandrine
Van Meerbeeck, Jan P.
Van Schil, Paul E.Y.
Raskin, Jo
Surmont, Veerle
Maat, Alexander P.W.M.
Yahia, Maha
Burgers, Sjaak A.
Pretzenbacher, Yassin
De Ryck, Frederic
Cornelissen, Robin
Klomp, Houke M.
Oliveira, Ana
Aerts, Joachim
Baas, Paul
Marreaud, Sandrine
Van Meerbeeck, Jan P.
Van Schil, Paul E.Y.
Source :
Raskin , J , Surmont , V , Maat , A P W M , Yahia , M , Burgers , S A , Pretzenbacher , Y , De Ryck , F , Cornelissen , R , Klomp , H M , Oliveira , A , Aerts , J , Baas , P , Marreaud , S , Van Meerbeeck , J P & Van Schil , P E Y 2024 , ' A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma : EORTC 1205 ' , The European respiratory journal , vol. 63 , no. 6 .
Publication Year :
2024

Abstract

BACKGROUND: The role of surgery in pleural mesothelioma remains controversial. It may be appropriate in highly selected patients as part of a multimodality treatment including chemotherapy. Recent years have seen a shift from extrapleural pleuropneumonectomy toward extended pleurectomy/decortication. The most optimal sequence of surgery and chemotherapy remains unknown. METHODS: EORTC-1205-LCG was a multicentric, noncomparative phase 2 trial, 1:1 randomising between immediate (arm A) and deferred surgery (arm B), followed or preceded by chemotherapy. Eligible patients (Eastern Cooperative Oncology Group 0-1) had treatment-naìˆve, borderline resectable T1-3 N0-1 M0 mesothelioma of any histology. Primary outcome was rate of success at 20 weeks, a composite end-point including 1) successfully completing both treatments within 20 weeks; 2) being alive with no signs of progressive disease; and 3) no residual grade 3-4 toxicity. Secondary end-points were toxicity, overall survival, progression-free survival and process indicators of surgical quality. FINDINGS: 69 patients were included in this trial. 56 (81%) patients completed three cycles of chemotherapy and 58 (84%) patients underwent surgery. Of the 64 patients in the primary analysis, 21 out of 30 patients in arm A (70.0%; 80% CI 56.8-81.0%) and 17 out of 34 patients (50.0%; 80% CI 37.8-62.2%) in arm B reached the statistical end-point for rate of success. Median progression-free survival and overall survival were 10.8 (95% CI 8.5-17.2) months and 27.1 (95% CI 22.6-64.3) months in arm A, and 8.0 (95% CI 7.2-21.9) months and 33.8 (95% CI 23.8-44.6) months in arm B. Macroscopic complete resection was obtained in 82.8% of patients. 30- and 90-day mortality were both 1.7%. No new safety signals were found, but treatment-related morbidity was high. INTERPRETATION: EORTC 1205 did not succeed in selecting a preferred sequence of pre- or post-oper

Details

Database :
OAIster
Journal :
Raskin , J , Surmont , V , Maat , A P W M , Yahia , M , Burgers , S A , Pretzenbacher , Y , De Ryck , F , Cornelissen , R , Klomp , H M , Oliveira , A , Aerts , J , Baas , P , Marreaud , S , Van Meerbeeck , J P & Van Schil , P E Y 2024 , ' A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma : EORTC 1205 ' , The European respiratory journal , vol. 63 , no. 6 .
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1452811607
Document Type :
Electronic Resource